Market Cap 6.03B
Revenue (ttm) 0.00
Net Income (ttm) -463.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,205,319
Avg Vol 1,754,632
Day's Range N/A - N/A
Shares Out 130.91M
Stochastic %K 88%
Beta 1.07
Analysts Strong Sell
Price Target $98.00

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 837 0111
Website: vaxcyte.com
Address:
825 Industrial Road, Suite 300, San Carlos, United States
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:26 AM
$PCVX is currently trading at $45.55, showing a bullish market context as it is near the 60D high of $46.3. The RSI at 60.02 indicates that the stock is approaching overbought territory but is not yet overextended, suggesting potential for further upside. The MA30 at $43.04 and MA50 at $39.17 indicate a strong upward trend, supporting a bullish bias. Suggested entry is at $45.60, slightly above the current close to confirm momentum. Set a stop loss at $43.50 to manage risk, which is below the MA30. For targets, aim for $47.00 as the first target, just above the 60D high, and $48.50 as a second target, which allows for a reasonable upside based on the current trend. Overall, the analysis supports a bullish position with a focus on momentum and trend indicators. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:32 AM
$PCVX is currently trading at $45.66, near its 60-day high of $45.99, indicating strong upward momentum. The RSI of 59.21 suggests that the stock is approaching overbought territory but is not yet there, which could allow for further upside. The 30-day moving average (MA30) at $42.59 and the 50-day moving average (MA50) at $38.62 both indicate a bullish trend, as the current price is significantly above these averages. For a trade plan, consider entering at the current price of $45.66. Set a stop loss at $43.43, just below the MA30, to manage risk. Target 1 could be set at $46.50, just below the 60-day high, while Target 2 could be $47.50, allowing for potential continuation if momentum persists. This plan leverages the current bullish context while maintaining a disciplined approach to risk management. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:08 AM
$PCVX is currently trading at $45.66, near its 60-day high of $45.99, indicating strong upward momentum. The RSI of 59.21 suggests that the stock is approaching overbought territory but is not yet there, which could allow for further upside. The 30-day moving average (MA30) at $42.59 and the 50-day moving average (MA50) at $38.62 both indicate a bullish trend, as the current price is significantly above these averages. For a trade plan, consider entering at the current price of $45.66. Set a stop loss at $43.43, just below the MA30, to manage risk. Target 1 could be set at $46.50, just below the 60-day high, while Target 2 could be $47.50, allowing for potential continuation if momentum persists. This plan leverages the current bullish context while maintaining a disciplined approach to risk management. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 10:31 AM
BTIG has updated their rating for Vaxcyte ( $PCVX ) to Buy with a price target of 85.
0 · Reply
Whiskey1679
Whiskey1679 Oct. 31 at 8:43 PM
https://whiskeyspennypicks.com/ After Hour Gainers: $UPWK $ABP $PCVX $ADTN $CHGG Latest Financial News on Penny Stocks: https://www.google.com/search?q=latest+financial+news+headlines+on+Penny+Stocks+Oct.+31st+2025&sca_esv=29c51f0230a7431d&rlz=1C1SYRH_enUS1184US1184&sxsrf=AE3TifOodya2BXn_aBP9768b7RH8qizO4Q%3A1761943279613&ei=7x4FacedJaiikPIPw5Hw6AI&ved=0ahUKEwiH0a6aps-QAxUoEUQIHcMIHC0Q4dUDCBM&uact=5&oq=latest+financial+news+headlines+on+Penny+Stocks+Oct.+31st+2025&gs_lp=Egxnd3Mtd2l6LXNlcnAiPmxhdGVzdCBmaW5hbmNpYWwgbmV3cyBoZWFkbGluZXMgb24gUGVubnkgU3RvY2tzIE9jdC4gMzFzdCAyMDI1SMlFUMoHWONDcAR4AZABAJgB9wKgAfIaqgEIMS4xMS4zLjO4AQPIAQD4AQGYAhSgAs0bwgIKEAAYsAMY1gQYR8ICBRAhGKABwgIFECEYqwKYAwCIBgGQBgiSBwg0LjEwLjMuM6AHulWyBwgwLjEwLjMuM7gHlRvCBwkwLjEuOS45LjHIB78B&sclient=gws-wiz-serp
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 10 at 4:40 PM
@outlawinvestor1 Have you ever looked at $PCVX ? I looked at PCVX hard 2-3 years ago after they published their Phase 2 data that showed their vaccine outperformed Prevnar from $PFE not only providing (just slightly) better efficacy in the same serotypes as Prevnar but protected against 2-3 more. If I recall correctly there are 27 serotypes of pneumonia of which Prevnar protected against 20 or 21 (something like that). PCVX's protected against 23 or 24 of the 27. I could be wrong which is why I am asking. I do not get a consistent answer via Google. At the time, it appeared PCVX's vaccine would take an enormous share from Prevnar that was doing $7.5B/year at the time. I do not recall a specific reason why PCVX's share price collapsed but it has began rising again. They are even up today which is somewhat telling. No worries if you are unfamiliar. Hope all is well.
2 · Reply
QuickFlipNinja
QuickFlipNinja Oct. 5 at 4:44 PM
$PCVX Vaccine technology growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 9:37 PM
$PCVX: Unusual Options Activity Alerted CALL flow observed 250x contracts at Strike price of $35 Exp on 11/21/2025 with Premium of $123K and showing BEARISH Sentiment
0 · Reply
olaisamuffin
olaisamuffin Oct. 3 at 5:06 PM
$PCVX filling the gap ?
0 · Reply
swampwiz0
swampwiz0 Sep. 17 at 8:56 PM
$PCVX Wow, less than a year ago, this puppy was selling for $114.
1 · Reply
Latest News on PCVX
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025, 8:00 AM EDT - 7 months ago

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors


Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 8 months ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI


Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 3:26 AM EST - 9 months ago

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript


Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 4:05 PM EST - 10 months ago

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference


Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Jan 30, 2025, 11:51 AM EST - 10 months ago

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm


Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

Jan 15, 2025, 7:15 AM EST - 10 months ago

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

PFE


Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 4, 2024, 11:58 PM EDT - 1 year ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering


Vaxcyte Appoints John Furey to Board of Directors

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Vaxcyte Appoints John Furey to Board of Directors


Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 12:32 AM EST - 1 year ago

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript


Vaxcyte Announces Pricing of $750 Million Public Offering

Jan 30, 2024, 11:37 PM EST - 1 year ago

Vaxcyte Announces Pricing of $750 Million Public Offering


Vaxcyte Appoints Whitney Jones as Chief People Officer

Jan 16, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Appoints Whitney Jones as Chief People Officer


PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:26 AM
$PCVX is currently trading at $45.55, showing a bullish market context as it is near the 60D high of $46.3. The RSI at 60.02 indicates that the stock is approaching overbought territory but is not yet overextended, suggesting potential for further upside. The MA30 at $43.04 and MA50 at $39.17 indicate a strong upward trend, supporting a bullish bias. Suggested entry is at $45.60, slightly above the current close to confirm momentum. Set a stop loss at $43.50 to manage risk, which is below the MA30. For targets, aim for $47.00 as the first target, just above the 60D high, and $48.50 as a second target, which allows for a reasonable upside based on the current trend. Overall, the analysis supports a bullish position with a focus on momentum and trend indicators. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:32 AM
$PCVX is currently trading at $45.66, near its 60-day high of $45.99, indicating strong upward momentum. The RSI of 59.21 suggests that the stock is approaching overbought territory but is not yet there, which could allow for further upside. The 30-day moving average (MA30) at $42.59 and the 50-day moving average (MA50) at $38.62 both indicate a bullish trend, as the current price is significantly above these averages. For a trade plan, consider entering at the current price of $45.66. Set a stop loss at $43.43, just below the MA30, to manage risk. Target 1 could be set at $46.50, just below the 60-day high, while Target 2 could be $47.50, allowing for potential continuation if momentum persists. This plan leverages the current bullish context while maintaining a disciplined approach to risk management. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:08 AM
$PCVX is currently trading at $45.66, near its 60-day high of $45.99, indicating strong upward momentum. The RSI of 59.21 suggests that the stock is approaching overbought territory but is not yet there, which could allow for further upside. The 30-day moving average (MA30) at $42.59 and the 50-day moving average (MA50) at $38.62 both indicate a bullish trend, as the current price is significantly above these averages. For a trade plan, consider entering at the current price of $45.66. Set a stop loss at $43.43, just below the MA30, to manage risk. Target 1 could be set at $46.50, just below the 60-day high, while Target 2 could be $47.50, allowing for potential continuation if momentum persists. This plan leverages the current bullish context while maintaining a disciplined approach to risk management. https://privateprofiteers.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 10:31 AM
BTIG has updated their rating for Vaxcyte ( $PCVX ) to Buy with a price target of 85.
0 · Reply
Whiskey1679
Whiskey1679 Oct. 31 at 8:43 PM
https://whiskeyspennypicks.com/ After Hour Gainers: $UPWK $ABP $PCVX $ADTN $CHGG Latest Financial News on Penny Stocks: https://www.google.com/search?q=latest+financial+news+headlines+on+Penny+Stocks+Oct.+31st+2025&sca_esv=29c51f0230a7431d&rlz=1C1SYRH_enUS1184US1184&sxsrf=AE3TifOodya2BXn_aBP9768b7RH8qizO4Q%3A1761943279613&ei=7x4FacedJaiikPIPw5Hw6AI&ved=0ahUKEwiH0a6aps-QAxUoEUQIHcMIHC0Q4dUDCBM&uact=5&oq=latest+financial+news+headlines+on+Penny+Stocks+Oct.+31st+2025&gs_lp=Egxnd3Mtd2l6LXNlcnAiPmxhdGVzdCBmaW5hbmNpYWwgbmV3cyBoZWFkbGluZXMgb24gUGVubnkgU3RvY2tzIE9jdC4gMzFzdCAyMDI1SMlFUMoHWONDcAR4AZABAJgB9wKgAfIaqgEIMS4xMS4zLjO4AQPIAQD4AQGYAhSgAs0bwgIKEAAYsAMY1gQYR8ICBRAhGKABwgIFECEYqwKYAwCIBgGQBgiSBwg0LjEwLjMuM6AHulWyBwgwLjEwLjMuM7gHlRvCBwkwLjEuOS45LjHIB78B&sclient=gws-wiz-serp
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 10 at 4:40 PM
@outlawinvestor1 Have you ever looked at $PCVX ? I looked at PCVX hard 2-3 years ago after they published their Phase 2 data that showed their vaccine outperformed Prevnar from $PFE not only providing (just slightly) better efficacy in the same serotypes as Prevnar but protected against 2-3 more. If I recall correctly there are 27 serotypes of pneumonia of which Prevnar protected against 20 or 21 (something like that). PCVX's protected against 23 or 24 of the 27. I could be wrong which is why I am asking. I do not get a consistent answer via Google. At the time, it appeared PCVX's vaccine would take an enormous share from Prevnar that was doing $7.5B/year at the time. I do not recall a specific reason why PCVX's share price collapsed but it has began rising again. They are even up today which is somewhat telling. No worries if you are unfamiliar. Hope all is well.
2 · Reply
QuickFlipNinja
QuickFlipNinja Oct. 5 at 4:44 PM
$PCVX Vaccine technology growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum.
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 9:37 PM
$PCVX: Unusual Options Activity Alerted CALL flow observed 250x contracts at Strike price of $35 Exp on 11/21/2025 with Premium of $123K and showing BEARISH Sentiment
0 · Reply
olaisamuffin
olaisamuffin Oct. 3 at 5:06 PM
$PCVX filling the gap ?
0 · Reply
swampwiz0
swampwiz0 Sep. 17 at 8:56 PM
$PCVX Wow, less than a year ago, this puppy was selling for $114.
1 · Reply
elmarklimke
elmarklimke Sep. 5 at 8:26 PM
$PCVX it is time to go up
0 · Reply
justiceforb_85
justiceforb_85 Aug. 8 at 1:00 AM
$PCVX look forward to VAX-31 entering the clinic. Company with significant cash reserve but timeline in long.
0 · Reply
OptionRunners
OptionRunners Aug. 7 at 3:05 PM
$PCVX Buyer of the December 19th $30 calls 1,000 times for $4.80-$4.90 Buying into this earnings sell off
0 · Reply
d_risk
d_risk Aug. 7 at 1:15 AM
$PCVX - Vaxcyte Inc. Common Stock - 10Q - Updated Risk Factors PCVX’s 10-Q risk update spotlights pipeline shifts with paused/discontinued candidates, intensified focus on VAX-31 Phase 3, expanded regulatory and manufacturing complexities, evolving ACIP guidelines, heightened financial losses, and new risks around data variability, AI use, cybersecurity, global trials, IP litigation, and ESG compliance—all amid a challenging competitive and policy landscape. #Biotechnology #Cybersecurity #FinancialRisk #RegulatoryCompliance #VaccineDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/PCVX/10-Q/2025-08-06
0 · Reply
joe77w
joe77w Aug. 1 at 3:10 AM
$STRO $PCVX $EXEL worth more dead than alice, STRO worth at least 2.5usd if liquidate imo
0 · Reply
Icarus81
Icarus81 Jul. 30 at 6:21 AM
$PCVX Prasad gone is a positive for PCVX. Go time 🚀🚀
0 · Reply
peterb030
peterb030 Jul. 17 at 2:52 PM
$LAES oke now its looking better $NVTS up $0.01 🫣 $PCVX gonna be one to watch(allready in 36.02) $BBAI not selling
0 · Reply
peterb030
peterb030 Jul. 17 at 5:56 AM
$PCVX Wall Street’s Bullish Outlook: Triple-Digit Upside Potential Wall Street is overwhelmingly bullish on Vaxcyte. The company currently trades around $33.40, but analysts see significant upside over the next 12 months. Based on the average one-year price target provided by eight analysts, Vaxcyte’s fair value sits at $125.75, implying a potential upside of more than 276%. The high-end estimate reaches as far as $163.00, while the low-end remains above $65.00—still nearly double the current trading price.
0 · Reply
osvaldo
osvaldo Jul. 16 at 2:26 PM
$PCVX reckon the FDA will loose their positioning about vaccines while the PCVX trials still are developing to get some results, say 2h '26.
0 · Reply
JPB415
JPB415 Jul. 8 at 6:51 PM
$PCVX This damn stock always fizzle before closing
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 7 at 9:25 AM
$PCVX Brilliant piece that captures PCVX's situation perfectly. So if you want to update your understanding of PCVX or get to know PCVX better, this is essential reading. https://beyondspx.com/article/vaxcyte-s-high-fidelity-approach-unlocking-broad-spectrum-vaccine-potential-pcvx
1 · Reply